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Background: Vascular endothelial growth factor (VEGF) is a potent multifunctional cytokine which plays a key role
in the pathogenesis of diabetic micro-vascular complications. Human VEGF gene is said to be highly polymorphic.
Insertion/deletion (I/D) polymorphism of the 18 bp fragment at −2549 position of the promoter region in VEGF
gene is said to be of particular interest. The study was aimed to evaluate association of Insertion/deletion (I/D)
polymorphism of the 18 bp fragment at −2549 position of the promoter region in VEGF gene, with diabetic
nephropathy in type 2 diabetes mellitus.
Methods: This cross sectional study enrolled 40 subjects each of diabetic nephropathy (DN), diabetes mellitus
without nephropathy (DM) and normal control subjects. DNA was isolated from peripheral blood leukocytes.
Genotyping of the VEGF gene insertion/ deletion (I/D) polymorphism was done by the polymerase chain reaction
(PCR) methods. The frequency of VEGF alleles and genotype distribution were compared in diabetic nephropathy,
uncomplicated diabetic and control groups.
Results: DD genotype and D allele were found to be significantly associated with DN group (p = 0.009 and 0.02
respectively) in comparison to DM group. Also DD genotype conferred significant risk of diabetic nephropathy in
DM group (OR = 4.2) (against combined frequency of ID and II genotype) so does D allele 2.09 (against I allele).
Conclusion: DD genotype and D allele in I/D polymorphism at −2549 position of VEGF gene is associated with
increased susceptibility to diabetic nephropathy in north Indian population.
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Diabetic nephropathy (DN) is the leading cause of
chronic kidney disease in patients being prescribed renal
replacement therapy [1] and is associated with increased
cardiovascular mortality [2]. 20%-40% of patients with
type 2 diabetes mellitus (DM) ultimately develop nephrop-
athy, but the reason why only some and not all patients
with diabetes develop this complication is unknown [3,4].* Correspondence: alpanasaxena@hotmail.com
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unless otherwise stated.Previously glycemic control and duration of diabetes were
said to be the two principle causes of progression to DN,
but variable outcomes in patients with relatively same
glycemic status and duration of DM have indicated role
of environmental factors and genetic susceptibility to
the condition [5]. Hyperglycaemia induced complex inter-
actions between metabolic and hemodynamic changes,
along with variable genetic predisposition, sets the stage
for kidney injury, as for other diabetic complications [6].
Relatively earlier onset of diabetes as compared to their
European counterparts and increasing longevity amongst
Asian population has been proposed to be leading tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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exposure to hyperglycaemia [7]. Evidence of abnormal
angiogenesis has been found in patients with DN in both
type 1 and type 2 diabetes mellitus [8-10].
Vascular endothelial growth factor (VEGF), a potent
multifunctional cytokine and highly conserved homodi-
meric glycoprotein, has been proposed to play key role in
the pathogenesis of diabetic micro-vascular complications
by virtue of its role in angiogenesis and micro-vascular
permeability [11-13]. VEGF, also known as vascular per-
meability factor is one of the most potent inducers of
micro vascular permeability [14]. VEGF-A (also called
VEGF), most predominant of the VEGF isoforms, have
been shown to be significantly elevated in type 2 dia-
betic patients and the levels are positively correlated with
urinary albumin creatinine ratio [15]. Role of VEGF is
well established in Diabetic retinopathy and has led to
therapeutic application of this knowledge. Thus studies
association of VEGF in diabetic nephropathy can be
beneficial to this patient population. The genetic varia-
tions in the VEGF gene can influence levels of VEGF
protein expression.
Several polymorphisms in VEGF gene have been studied
in respect to DN and some of them have been associated
with altered serum and urine levels of VEGF [16-20].
Human VEGF gene spans 16,272 bp on chromosome 6
(6p12). It consists of eight exons and it is said to be
highly polymorphic [21]. Insertion/deletion (I/D) poly-
morphism of the 18 bp fragment at −2549 position of
the promoter region in VEGF gene has been implicated
in a number of diseases with angiogenic basis and hence
is of particular interest [22-24]. Asian Indian is ethnic-
ally distinct population with leading number of diabetic
patients in the world. Concept of both the “thrifty geno-
types” and “thrift phenotype” holds true for Indian
population. This has been proposed to cause increased
predisposition to Diabetes mellitus and thus to asso-
ciated complications [25,26]. In this light there is need
to study various Genetic associations of diabetes and
diabetic complications in Indian population. The study
was to evaluate association of Insertion/deletion (I/D)
polymorphism of the 18 bp fragment, at −2549 position
of the promoter region in VEGF gene, with diabetic
nephropathy in north Indian population.
Methods
Design and subject
This case control study enrolled 40 subjects each with
diabetic nephropathy (DN), type 2 diabetes mellitus
without nephropathy (DM) and 40 normal control
subjects. Type 2 diabetes was diagnosed on the basis of
the WHO criteria [2]. Diabetic nephropathy status was
determined on the basis of questionnaires, clinical features
and laboratory data. Albumin creatinine ratio was used todiagnose diabetic nephropathy and those having macro-
albuminuria (ACR > 300 mg/g of creatinine) were in-
cluded as diabetic nephropathy subjects. Subjects with
history suggestive of urinary tract infection, nephro-
lithiasis, acute inflammatory diseases, hematologic dis-
eases, neoplastic diseases and pregnancy were excluded
from the study. Control subjects were 40 age and sex
matched healthy volunteers with no history of diabetes
or any major clinical disorders and had normal fasting
plasma glucose level. Study was approved by ethical
committee Maulana Azad Medical College and associ-
ated hospitals, New Delhi-110002, INDIA.
Methods
After obtaining informed written consent, medical history
was elicited. 6 ml of fasting venous blood was obtained
after overnight fasting for plasma glucose level, serum
urea, creatinine, lipid profile and serum electrolyte esti-
mation. Serum and whole blood (in EDTA containing
vial) was stored at −80 degree for PCR. 10 ml of early
morning spot urine sample was obtained for urinary
microalbumin estimation. Plasma glucose, serum urea,
creatinine, HDL, LDL, Triglycerides, Cholesterol level were
estimated on Syncron DXC® clinical chemistry analyzer
(Beckman Coulter Ltd. USA) by standard methods.
Urinary microalbumin was assayed by turbidimetric
method and urinary creatinine by Modified Jaffe’s method
on Syncron CX5 clinical chemistry analyzer (Beckman
Coulter Ltd. USA).
Determination of the VEGF genotype
The official gene symbol for the gene is VEGF-A, ap-
proved name is Vascular endothelial growth factor and
location is chromosome6 (6p12). Polymorphism selected
for the present study was Insertion/Deletion (I/D) poly-
morphism of 18 bp fragment at −2549 position of the pro-
moter region in VEGF gene. It was located at the promoter
region of VEGF gene based on its functional nature.
High molecular weight genomic DNA was isolated
from peripheral blood leukocytes by ‘GENEAID® DNA
extraction kit’ (GeneAid Taiwan, Cat. # GEB100). The




The amplification was accomplished with a 50 ul reac-
tion mixture containing 5 ul of 20 ng template DNA,
0.25 ul of 25pmol each Primers, 2.5 ul 10 mM dNTPs,
1.5 ul of 20 mM MgCl2, 0.3 ul of 5 U/ul Taq polymerase
with 2.5 ul of 10X Taq Buffer . The amplification condi-
tions were 6 min of initial denaturation at 95°C; 35
cycles at 94°C for 1min, annealing temperature at 58.8°C
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sion step at 72°C.The amplification products were sepa-
rated by electrophoresis on 2.5% agarose gel stained
with ethidium bromide. For the VEGF I/D polymorph-
ism two bands were observed, 211 bp for D allele and
229 bp for I allele as shown Figure 1
Statistical analysis
The data were analyzed using the statistical package
SPSS (version 15). Quantitative variables were expressed
as mean ± standard deviation or median depending on
whether the data was normally distributed. Qualitative
variables were expressed as number and percentage.
Statistical differences between categorical data like gen-
der, genotype distribution were tested using Chi Square
test. Independent sample t test was used for qualitative
variables and normally distributed variables like age,
FBS, total cholesterol and triglycerides were analyzed by
ANOVA (analysis of variance). Associations of genotypes
and alleles were assessed as OR and 95% confidence
intervals (CI). Differences by univariate methods (χ2 test,
unpaired Student t test) were analyzed together in a
logistic regression analysis to test for significant risk
factors for diabetic nephropathy. Values less than or
equal to 0.05 were considered statistically significant.
Results
The distribution of the VEGF DD genotype was signifi-
cantly different in patients with diabetic retinopathy
compared with healthy controls, entire diabetic group
and patients with no complications.Figure 1 VEGF Insertion/Deletion (I/D) polymorphism of 18 bp fragm
Legend. Lane 1, 2, 6, 7, 8, 12-17 - 211bp and 229bp (I/D). Lane 1, 2, 6, 7, 8,Table 1 shows the baseline characteristics of the study
population. All the three groups are age (p = 0.78) and
sex (p = 0.06) matched. Also there was no statistically
significant difference between DM and DN subjects
regarding duration of diabetes (0.78). Significant increase
in fasting blood sugar (p < 0.0001), total cholesterol (p =
0.46), triglycerides (p < 0.0001), serum urea (p < 0.0001),
serum creatinine (p < 0.0001) and urinary albumin cre-
atinine ratio (p < 0.0001) was noted in patients compared
to controls.
Table 2 showed that there was statistically significant
difference in genotype distribution (p = 0.02) and allele
frequencies (p = 0.02) of the I/D polymorphism between
the three groups in general. Further there was statisti-
cally significant difference in DM and DN in terms of
both genotypes (0.009) and allels (0.02) with increased
frequency of DD genotype (55% Vs 22.5%) and D allele
(68.75% Vs 50%) in DN group. Also against controls, DD
genotype (p = 0.02, 55%Vs27.5%) and D allele (p = 0.01,
68% Vs 51.25%) frequency were found to be significantly
increased in DN group. But such significance of differ-
ence was lacking between controls and DM both in
terms of genotype and Allelic frequency (p = 0.79 and
0.5 respectively). Odds ratio (OR) was calculated be-
tween DN and DM group for risk conferred by DD
genotype when compared combined frequency of II and
ID genotype (to represent total non DD population).
Odds of developing diabetic nephropathy were found to
be 4.2 (95% confidence interval 1.28-4.63) in diabetic
patients with DD genotype when compared to diabetic
population with II and ID genotype together. Odds ofent at –2549 position of the promoter region in VEGF gene.
12-17- 211bp for D. L-100bl DNA ladder.
Table 1 shows the baseline characteristics of the study population
Control (40) Diabetes Mellitus (DM) (40) Diabetic Nephropathy (DN) (40) P value
Gender Male 16 18 20 0.06
Female 24 22 20
Duration of diabetes 11.2 (8-15) 12.4(10-16) 0.78
Age 50±4.41 50.5±5.5 51±4.4 0.88
FBS (mg %) 84±7.6 166.2±62.2 169±60.2 <0.0001
Total Cholesterol (mg %) 168±25.7 178±33 179±39 0.46
Triglyserides (mg %) 105±28.4 139±48.9 175±81 <0.0001
S. Urea (mg %) 22±5.2 50±5.5 51±4.4 <0.0001
S. Creatinine (mg %) 0.5±0.18 0.71±0.18 1.07±0.8 0.0001
Urinary ACR (mg/g of creatinine) 2.2(0-11) 5.83(0.04-235) 400(310-1.70) <0.0001
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(95% C.I. = 1.15-4.19) in diabetic patients with D allele
when compared to diabetic population with I allele.
The power of the present study for detecting the allelic
differences between diabetic nephropathy group subjects
and controls was calculated. It was found to be signifi-
cant (96% with α-error = 0.05, two tailed).
Discussion
In our study we discovered that DD polymorphism of
18 bp fragment at −2549 position of VEGF gene is
significantly associated with diabetic nephropathy. We
found significantly increased frequency of DD genotype
in DN group Vs DM group (p = 0.009), whereas there
was no statistically significant increase in frequency of
DD genotype in DM group when compared with control
group (p = 0.5). Control population here serves to repre-
sent the baseline frequency of genotype distribution in
normal population, and our finding further emphasizesTable 2 Genotype and Allele frequencies of VEGF variants in
Genotypes
II ID DD
Controls (40) 10 (25) 19 (47.5) 11 (2
DM (40) 9 (22.5) 22 (55) 9 (22
DN (40) 7 (17.5) 11 (27.5) 22 (5
Alleles
I D
Controls (40) 39 (48.75) 41 (51.25)
DM (40) 40 (50) 40 (50)@
DN (40) 25 (31.25) 55 (68.75)#
*p value 0.79 (statistically insignificant) Vs controls.
**p value 0.02 and 0.009 vs controls and DM group respectively.
aDN group Vs DM group against combined frequency of II and ID genotype.
@p value 0.5 (statistically insignificant) Vs controls.
#p value 0.01 and 0.02 vs controls and DM group respectively.
bDN group Vs DM group against frequency of I allele.the fact that those subjects amongst diabetic population
had DD genotype were at increased risk of diabetic ne-
phropathy (OR = 4.2, 95% C.I. = 1.28-4.63). The risk was
also found to be increased with D allele (OR = 2.21, 95%
C.I. = 1.15-4.19) in all subjects with diabetes mellitus
(DN +DM). This confers that DD genotype and D allele
has increased frequency in DN group than both control
and DM group and also is associated with significantly
increased risk of diabetic nephropathy.
Explanation to this can be provided by the fact that
VEGF by virtue of its property of increasing vascular
permeability and angiogenesis plays important role in
pathogenesis of diabetic micro-vascular complications.
VEGF has been demonstrated in human kidney in podo-
cytes, proximal and distal tubular cells and VEGF recep-
tors are found in pre, post and glomerular region and on
renal masengial cells [27]. Hyperglycemia is said to
increase VEGF expression by activating protein kinase C
(PKC) [28]. VEGF then leads to activation of manycontrols , DM and DN groups
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permeability, this particular action along with altered
NO synthesis in diabetic milieu can lead to proteinurea
[29]. VEGF increases permeability by different mechan-
ism which includes; increasing the diffusion rate of sub-
stances across a capillary, widening the junction between
endothelial cells and increasing their fenestrations; indu-
cing the formation of vesiculo-vacuolar organelles and
caveolae [30]. Other mechanisms proposed are; in-
creased production of α3 chain of collagen, plasminogen
activators and chemokine attractants, along with recruit-
ment of macrophages [12].
VEGF gene has been found to be associated with dia-
betic micro vascular complications in studies with VEGF
C (−634) G, VEGF (−460), VEGF + 405 and many other
polymorphism [11,17,31]. Polymorphisms in promoter
region are said to be associated with altered level of serum
VEGF [30-34]. Current I/D polymorphism have been to
date studied only in two studies, in relation to diabetic
nephropathy, to the best of our knowledge [19,20]. Finding
of the study by Yang et al. [20] goes in favor of our study
which says that DD genotype is associated with diabetic
nephropathy. Possible explanation given is that D allele is
said to be associated with increased transcription of VEGF
compared to I allele leading to raised serum levels, further
causing the effects. Effect of DD genotype has been also
found to be associated with increased serum levels of
VEGF by Buraczynska et al. [19]. Though the effect was
not statistically significant, this was attributed to very
small sample size (20 in each group). In contrast to our
study Buraczynska et al. [19] reported no significant asso-
ciation of DD genotype in diabetic nephropathy subjects
but they have suspected type II error in the study.Conclusion
We conclude that, DD genotype and D allele in I/D poly-
morphism at −2549 position of VEGF gene is associated
with increased susceptibility to diabetic nephropathy in
north Indian population. Our study is the first study to
assess this polymorphism in diabetic nephropathy subjects
in Indian population and only second in world to do so to
the best of our knowledge. We recommend multicentre
studies with larger sample size and including serum VEGF
levels to further establish and clarify the role of VEGF and
I/D polymorphism in diabetic nephropathy.
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